Mainz Biomed (NASDAQ:MYNZ) Trading 2.7% Higher – Time to Buy?

Mainz Biomed NV (NASDAQ:MYNZ) traded up 2.7% during mid-day trading on Tuesday . The company traded as high as $1.23 and last traded at $1.15. 188,970 shares were traded during trading, an increase of 4% from the average session volume of 182,289 shares. The stock had previously closed at $1.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Mainz Biomed Price Performance

The stock has a market cap of $9.87 million, a PE ratio of -0.02 and a beta of 0.27. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. The business has a 50 day moving average price of $1.27 and a two-hundred day moving average price of $1.52.

Mainz Biomed (NASDAQ:MYNZ) last issued its quarterly earnings results on Friday, September 26th. The company reported ($1.32) EPS for the quarter. The company had revenue of $0.14 million during the quarter. Research analysts expect that Mainz Biomed NV will post -23.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mainz Biomed

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC increased its stake in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 285,000 shares of the company’s stock after buying an additional 88,400 shares during the quarter. Armistice Capital LLC owned 6.23% of Mainz Biomed worth $402,000 at the end of the most recent quarter.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.